Management of Substance Use Disorder in Pregnant People With HIV


Leah J. Leisch, MD
University of Alabama at Birmingham
Birmingham, AL


Sandra A. Springer, MD
Yale School of Medicine
New Haven, CT

August 6, 2024

10:00 AM – 11:15 AM PT


Assessment of Needs

Substance use disorder, including the misuse of opioids, may disproportionately affect people with HIV. It is essential that clinicians who treat patients with HIV recognize the signs of opioid use disorder and understand the current treatment options and challenges.

Drug Enforcement Agency certificate holders are now required to complete 8 hours of training on opioids, substance use disorders (SUDs), and pain management. The IAS–USA is excited to support you in meeting these new requirements with numerous training options to help you provide the best possible care for your HIV patients! This webinar, presented by Leah J. Leisch, MD, and moderated by Sandra Springer, MD, focuses on the management of substance use disorder in pregnant people with HIV.

Learning Objectives

On completion of this activity, learners will be able to:

  • Discuss the 3 US Food and Drug Administration-approved medications for opioid use disorder and how they relate to the care of patients who are pregnant, planning to become pregnant, or breastfeeding
  • Facilitate patient-centered decision-making when considering various protocols for buprenorphine initiation in patients with HIV who have been using fentanyl and are pregnant
  • Appreciate the complexity of the social and legal constructs impacting care for patients with current or past substance use who are now pregnant


Who Should Attend

This webinar is designed for clinical decision-makers who are actively involved in HIV care and research, including physicians, physician assistants, nursing professionals, and other health care professionals.

Individual registration is required in order to receive CME credit or a certificate of participation.

Registration closes on Tuesday, August 6, 2024, 10:30 AM (PT).

For more information or questions, please contact the registration department at or 415-544-9400.

Conflicts of Interest

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities. 

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”

IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenter and planners/reviewers is below and in the slides prior to the presentation of educational content.


Dr Leisch reported no relevant financial relationships with ineligible companies. (Updated May 13, 2024)


Dr Springer reported receiving consulting fees from Alkermes, Inc, and receiving in-kind study drug donations from Alkermes, Inc, and Indivior, Inc. (Updated February 2, 2024)


Planner/Reviewer 1 reported no relevant financial relationships with ineligible companies (Updated May 15, 2024)
Planner/Reviewer 2 reported no relevant financial relationships with ineligible companies (Updated May 22, 2024)

COW Board

The financial relationships of the COW Board can be found here: 

CME Credits

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. IAS-USA, the CME activity provider, will submit your participant information (eg, name, date of birth, activity credits earned, ABIM MOC number) to ABIM through the PARS system for the purpose of reporting ABIM MOC credits.

Nursing Credits

This activity is eligible for ANCC credit, see final CNE activity announcement for specific details.

Pharmacy Credits

Accreditation Council for Pharmacy Education logoThis activity is eligible for ACPE credit, see final CPE activity announcement for specific details.

Grant Support

This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from ineligible companies. Per IAS–USA policy, any effort that uses grants from ineligible companies must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.


Gilead Sciences, Inc.
Merck & Co, Inc.
ViiV Healthcare

Frequently Asked Questions

View our list of FAQs about attending a webinar.

Further Questions?
Please contact the registration department at or 415-544-9400.